Cytori has developed technology designed to assist the physician in reconstructive and aesthetic surgery procedures. The company’s mission is to improve the quality and length of life by providing innovative regenerative therapies to patients. Their key technology is the Celution® 700 system that prepares an autologous tissue graft for delivery back to the patient in the same surgical procedure.

Although Celution® is currently unavailable in the U.S., the technology is under review by the US Food and Drug Administration (FDA) and commercially available in many countries in Europe and Asia. Cytori is actively pursuing the expansion of their distributor network to target distributor partnerships in South America as well as other regions. The company is also investigating the possibility of using their technology for indications beyond reconstructive and aesthetic surgery.

The Celution® 900/MB System is the foundation of the company’s StemSource™ Cell Bank. This cell bank enables hospitals in Japan to offer patients the service of cryopreserving their adipose-derived adult stem and regenerative cells (ADRCs) to potentially save their lives in the event they are required for future medical treatment. Research and development has shown that cord blood stem cells have tremendous future value for treating blood disorders and genetic diseases.

In addition, Cytori is exploring the possibility of using adipose-derived stem and regenerative cells (ADRCs), processed with their Celution® 800/CV System, to treat heart disease. The company recognizes the tremendous need for new therapies to repair heart muscle damaged from heart attacks or chronic heart conditions. Adipose tissue-derived stem and regenerative cells may become an effective treatment option for such conditions.